POCT09-A
Selection Criteria for Point-of-Care Testing Devices; Approved Guideline

This document provides guidance on selection of point-of-care testing devices based on the patient care setting and clinical needs. It is designed as an aid to laboratory and facility management to simplify and facilitate the selection process but also allows evaluation of devices to identify those that are optimal to the patient care setting and population served.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

**Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

**Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

**Appeals Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

**Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org
Selection Criteria for Point-of-Care Testing Devices; Approved Guideline

Volume 30 Number 8

Marcia L. Zucker, PhD  
Richard Anderson, PhD  
Juliet Carrara, MBA, RAC, CMQ/OE  
Sheila K. Coffman, MT(ASCP)  
Christine Cursio, MLT, BSc  
Betty Dollar, BSMT(ASCP), MHS  
Ellis Jacobs, PhD, DABCC, FACB

Raymond Jakubowicz  
Jeanniline Koehler, MT(ASCP)SBB, CLS(NCA)  
Thomas I. Koshy, PhD  
Sharon K. Norman, MBA, MT(ASCP)  
Mary Rozmanc, BHA, ART, MLT  
Debra Russell, MT(ASCP)

Abstract

Clinical and Laboratory Standards Institute document POCT09-A—Selection Criteria for Point-of-Care Testing Devices; Approved Guideline provides guidance on selection of point-of-care testing (POCT) devices based on the patient care setting and clinical needs. This guidance document is intended to reflect the selection process of instrumented diagnostic systems that can be used at or near the site of patient care. Overall, this guidance document is designed to assist and benefit personnel responsible for the evaluation, negotiation, and selection process including laboratory, management, and information technology. It includes discussions on important factors when considering POCT through clinical and operational needs assessment. In addition, regulatory and accreditation requirements on various POCT or devices are explained, along with the various appendices that serve as a tool for POCT device implementation.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Copyright ©2010 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

**Suggested Citation**


**Previous Edition:**
June 2009

**Reaffirmed:**
January 2017

ISBN 1-56238-722-7
ISSN 0273-3099
Contents

Abstract .................................................................................................................................................... i

Committee Membership........................................................................................................................ iii

Foreword .............................................................................................................................................. vii

1 Scope.......................................................................................................................................... 1

2 Introduction ................................................................................................................................ 1

3 Standard Precautions.................................................................................................................. 1

4 Terminology ....................................................................................................................................... 2
  4.1 A Note on Terminology ................................................................................................ 2
  4.2 Definitions ................................................................................................................... . 2
  4.3 Abbreviations and Acronyms ....................................................................................... 4

5 Why Consider Point-of-Care Testing? ....................................................................................... 4
  5.1 Outcomes ...................................................................................................................... 5

6 Clinical Needs Assessment ........................................................................................................ 6
  6.1 Manufacturer’s Supplied Information ........................................................................... 6
  6.2 Test Use Characteristics ............................................................................................ 6
  6.3 Patient Demographics ................................................................................................... 7
  6.4 Evaluating Potential Impact on Clinical Benefit/Medical Outcomes ....................... 7
  6.5 Additional Resources: Evidence-Based Medicine ........................................................ 8

7 Operational Needs Assessment .................................................................................................. 8
  7.1 Facilities and Materials Management Requirements for Point-of-Care Testing .......... 9
  7.2 Quality Control ............................................................................................................. 9
  7.3 Test Menu Selection ................................................................................................... 10
  7.4 Frequency of Test Performance .................................................................................. 10
  7.5 Personnel Resources ................................................................................................... 11

8 Point-of-Care Testing System Selection .................................................................................. 12
  8.1 Identifying Candidate Point-of-Care Testing Devices ................................................ 12
  8.2 Cost Assessment ......................................................................................................... 13
  8.3 Preliminary Evaluation ............................................................................................... 14
  8.4 Special Consideration Devices ................................................................................... 16

9 Regulatory and Accreditation Requirements ........................................................................... 16
  9.1 Point-of-Care Testing Quality Assurance and Quality Control Considerations ....... 17
  9.2 Informed Consent/Ethics Committee Approval .......................................................... 18

10 Implementation Checklist ........................................................................................................ 18
  10.1 Installation .................................................................................................................. 18
  10.2 Method Verification.................................................................................................... 20
  10.3 Documentation............................................................................................................ 22

11 Continuing Process for Quality Point-of-Care Testing......................................................... 22
## Contents (Continued)

- References ............................................................................................................................................. 24
- Appendix A. Determination of Need for a New Point-of-Care Testing System ..................................... 26
- Appendix B. Clinical Needs Assessment Comparison Worksheet .......................................................... 27
- Appendix C. Items to Consider When Comparing Point-of-Care Testing System Specifications .......... 28
- Appendix D. Cost Assessment Worksheets ............................................................................................... 30
- Appendix E. Test Operator’s Evaluation of Proposed Systems ................................................................. 32
- Appendix F. Preimplementation Checklist ............................................................................................... 33
- Summary of Delegate Comments and Subcommittee Responses ............................................................. 34
- The Quality Management System Approach .......................................................................................... 54
- Related CLSI Reference Materials ........................................................................................................ 56
Foreword

Currently, no consensus guidance is available that can be applied to select an appropriate point-of-care testing (POCT) device for clinical use. This guideline provides an overview of important considerations when comparing POCT devices and includes a draft checklist of criteria that users of the document can employ as a starting point for selecting a new device for clinical use. This can be used by each institution, clinic, or physician’s office laboratory to independently develop its own comparisons and rating systems. As with core laboratory devices, the implementation of POCT devices is subject to regulatory and accreditation requirements. Newer devices have a variety of operational features that can assist with clinical management, improve quality of testing, and enhance regulatory compliance, but there are no available consensus criteria for direct comparison of these features.

Overall, this guidance document is designed to assist and benefit personnel responsible for the evaluation, negotiation, and selection process, including laboratory, management, information technology (IT), and end users of the POCT system. Because some vendor sales representatives do not have a laboratory background, the in vitro diagnostic industry would also benefit from having a consensus guideline that would assist the sales force with product presentation and encouragement of customer feedback.

Key Words

Instrument, needs assessment, outcomes, point of care, quality control
Selection Criteria for Point-of-Care Testing Devices; Approved Guideline

1 Scope

This document is designed as an aid for laboratory and facility management to simplify and facilitate the point-of-care testing (POCT) device selection process and allow evaluation of these devices to identify those that are optimal for the patient care setting and population served. The device evaluation process will lead to an increased awareness of the device’s testing process and risk associated with use of the device. In addition, long-term benefits can be achieved with improved operational and compliance processes. Thus, patient care, quality, and compliance will be maximized.

This guidance document is intended to reflect the selection process of instrumented diagnostic systems that can be used at or near the site of patient care. Purposely excluded from this discussion are large central laboratory analyzers, noninstrumented testing (eg, dip sticks, visual read lateral flow devices), and handheld glucose meters, which are the subject of other CLSI guidance documents, either already existing (eg, CLSI document C30) or in development. Although these classes of diagnostics devices are excluded from specific discussion, many of the processes and concepts discussed herein have widespread utility across device classes.

2 Introduction

Increased robustness and integration capabilities to existing system networks have established POCT devices as comprehensive patient care solutions, expanding their demand beyond conventional health care institutions. The number of available device alternatives for any given analyte, coupled with the devices’ examination, operational, and connectivity attributes and associated potential risks can result in a complex selection process that can obscure important factors unique to the facility.

This document provides guidance on selection of POCT devices based on the patient care setting and clinical needs. The breadth of POCT to consider is wide and growing larger every year. Various vendors offer POCT for specific analytes, which include but are not limited to, cardiac markers, coagulation markers (including D-dimer), glucose, drugs of abuse, infectious diseases, occult blood testing, intact parathyroid hormone (iPTH), renal and reproductive function testing, chemistry (eg, bilirubin, lactate, magnesium, sodium, potassium, chloride, and ionized calcium), CO-oximetry (oxygen [O₂] saturation, carboxyhemoglobin, methemoglobin), and blood gas panels (pO₂, pCO₂, pH). There are benchtop and small floor model immunoassay and chemistry analyzers that are promoted as options for POCT. Molecular diagnostics technology is advancing so quickly that it is reasonable to envision POCT for DNA/RNA tests in the near future.

3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention. For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious disease, refer to CLSI document M29.
4 Terminology

4.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrologic community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization of Standardization (ISO), and the European Committee for Standardization (CEN) documents; and that legally required use of terms, regional usage, and different consensus timelines are important considerations in the harmonization process. In light of this, CLSI’s consensus process for development and revision of standards focuses on harmonization of terms to facilitate the global application of standards and guidelines.

All terms and definitions will be reviewed again for consistency with international use and revised appropriately during the next scheduled revision of this document.

4.2 Definitions

accuracy (measurement) – closeness of agreement between a measured quantity value and a true quantity value of a measurand (ISO/IEC Guide 99).4

analytical sensitivity – quotient of the change in an indication and the corresponding change in the value of a quantity being measured (ISO 15193).5

analytical specificity – ability of a measurement procedure to determine solely the quantity it purports to measure (ISO 15193).5

calibration – operation that, under specified conditions, in a first step, establishes a relation between the quantity values with measurement uncertainties provided by measurement standards and corresponding indications with associated measurement uncertainties and, in a second step, uses this information to establish a relation for obtaining a measurement result from an indication (ISO/IEC Guide 99).4

calibration verification – the assaying of materials of known concentration in the same manner as patient samples to substantiate the instrument or test system’s calibration throughout the reportable range for patient test results (US CFR 493.2, 24 January 2003).6

clinical reportable range (CRR) – the range of analyte values that a method can report as a quantitative result, allowing for specimen dilution, concentration, or pretreatment used to extend the measuring interval (C50).7

clinical sensitivity – the ability of a test under study to give a positive result for subjects having the disease/state in question (MM17).8

clinical specificity – the ability of a test under study to give a negative result for subjects not having the disease in question (MM17).8

corrective action – action to eliminate the cause of a detected nonconformity or other undesirable situation (ISO 9000); NOTE 1: There can be more than one cause for nonconformity; NOTE 2: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence (ISO 9000).9
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in the most current edition of CLSI document HS01—A Quality Management System Model for Health Care. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

- Documents and Records
- Organization
- Personnel
- Equipment
- Purchasing and Inventory
- Process Control
- Information Management
- Occurrence Management
- Assessments—External and Internal
- Process Improvement

POCT09-A addresses the QSEs indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

<table>
<thead>
<tr>
<th>Documents and Records</th>
<th>Organization</th>
<th>Personnel</th>
<th>Equipment</th>
<th>Purchasing and Inventory</th>
<th>Process Control</th>
<th>Information Management</th>
<th>Occurrence Management</th>
<th>Assessments—External and Internal</th>
<th>Process Improvement</th>
<th>Customer Service</th>
<th>Facilities and Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>C30</td>
<td>C30</td>
<td>C50</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>C24</td>
<td>C28</td>
<td>C30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GP02</td>
<td>GP11</td>
<td>POCT04</td>
<td>POCT04</td>
<td>POCT04</td>
<td>GP02</td>
<td>MM17</td>
<td>POCT04</td>
<td>M29</td>
<td>POCT04</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from CLSI document HS01—A Quality Management System Model for Health Care.
Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI document GP26—*Application of a Quality Management System Model for Laboratory Services* defines a clinical laboratory path of workflow, which consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

POCT09-A addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

<table>
<thead>
<tr>
<th>Preexamination</th>
<th>Examination</th>
<th>Postexamination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examination Ordering</td>
<td>Order</td>
<td>Sample Collection</td>
</tr>
<tr>
<td>Simple Transport</td>
<td>C54</td>
<td>Sample Receipt/Processing</td>
</tr>
<tr>
<td>Examination</td>
<td>Examination</td>
<td>Results review and Follow-up</td>
</tr>
<tr>
<td>Results interpretation</td>
<td>C50</td>
<td>Results reporting and Archiving</td>
</tr>
<tr>
<td>Sample Management</td>
<td>C30</td>
<td></td>
</tr>
</tbody>
</table>

Adapted from CLSI document HS01—*A Quality Management System Model for Health Care*.
Related CLSI Reference Materials∗


C50-A Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline (2007). This document provides a general understanding of mass spectrometry and the principles that dictate its application in the clinical laboratory. It includes guidance, references, and quality assurance markers that will assist with the implementation and correct operation of a mass spectrometry (MS) system for its many applications. Information on maintaining optimum performance, approaches to ensuring accurate and precise mass measurement, verification of methods, quality control of assays within and between instruments, instrument troubleshooting, sample preparation, interpretation of results, and limitations of the technology is included.

C54-A Verification of Comparability of Patient Results Within One Health Care System; Approved Guideline (2008). This document provides guidance on how to verify comparability of quantitative laboratory results for individual patients within a health care system.

EP05-A2 Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition (2004). This document provides guidance for designing an experiment to evaluate the precision performance of quantitative measurement methods; recommendations on comparing the resulting precision estimates with manufacturers’ precision performance claims and determining when such comparisons are valid; as well as manufacturers’ guidelines for establishing claims.


EP09-A2 Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Second Edition (2002). This document addresses procedures for determining the bias between two clinical methods and the design of a method comparison experiment using split patient samples and data analysis.

EP15-A2 User Verification of Performance for Precision and Trueness; Approved Guideline—Second Edition (2005). This document describes the demonstration of method precision and trueness for clinical laboratory quantitative methods using a protocol designed to be completed within five working days or less.

EP21-A Estimation of Total Analytical Error for Clinical Laboratory Methods; Approved Guideline (2003). This document provides manufacturers and end users with a means to estimate total analytical error for an assay. A data collection protocol and an analysis method that can be used to judge the clinical acceptability of new methods using patient specimens are included. These tools can also monitor an assay’s total analytical error by using quality control samples.

GP02-A5 Laboratory Documents: Development and Control; Approved Guideline—Fifth Edition (2006). This document provides guidance on development, review, approval, management, and use of policy, process, and procedure documents in the medical laboratory community.

GP11-A Basic Cost Accounting for Clinical Services; Approved Guideline (1998). This document provides principles and techniques to help laboratory managers establish a workable cost-accounting system.

∗CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.
Related CLSI Reference Materials (Continued)

M29-A3 Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005). Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

MM17-A Verification and Validation of Multiplex Nucleic Acid Assays; Approved Guideline (2008). This guideline provides recommendations for analytical variation and validation of multiplex assays, as well as a review of different types of biological and synthetic reference materials.

POCT04-A2 Point-of-Care In Vitro Diagnostic (IVD) Testing; Approved Guideline—Second Edition (2006). This document provides guidance to users of in vitro diagnostic (IVD) devices outside the clinical laboratory, to ensure reliable results comparable to those obtained within the clinical laboratory.
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI’s efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at clsi.org/eCLIPSE.

For more information, visit www.clsi.org today.